Back to top
more

Adamas Pharmaceuticals, Inc. (ADMS)

(Delayed Data from NSDQ)

$6.39 USD

6.39
241,532

+0.11 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $6.38 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

What's in the Card's for Sealed Air (SEE) in Q2 Earnings?

Sealed Air's (SEE) second-quarter 2018 results are likely to reflect benefits from rising demand for packaged proteins and convenience meals amid cost concerns.

    Acorda Files Parkinson's Drug Marketing Application in EU

    Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.

      Pharma Stocks Weighed Down by Competition, Generic Pressure

      Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.

        New Strong Sell Stocks for February 26th

        Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

          FDA Accepts Acorda's NDA for Parkinson's Disease Candidate

          FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.

            Parkinson's Disease Space Again Under Spotlight This Week

            Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.

              Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up

              Adamas (ADMS) shares climb on the commercial launch of Gocovri in the United States for treating dyskinesia in patients with Parkinson's disease. This is the first FDA approved drug for the ailment.

                Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija

                Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.

                  Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

                  Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.

                    Acorda Reports Death in Parkinson's Trials, Stock Down 40%

                    Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.

                      Megan Sanks headshot

                      Adamas Pharmaceuticals (ADMS) Stock Soars 41% After FDA Approval

                      Adamas Pharmaceuticals, Inc. (ADMS) skyrocketed 41% in midday trading on Friday after the Food and Drug Administration approved its Parkinson's drug, Gocovri.

                        Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars

                        Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.

                          Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options

                          High level of implied volatility makes Adamas Pharmaceuticals (ADMS) Stock lucrative to the option traders.

                            Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)

                            One stock that you may want to consider dropping is Adamas Pharmaceuticals, Inc. (ADMS), which has witnessed a significant price decline in the past four weeks

                              Adamas Provides Positive Long-term Data on Parkinson's Drug

                              Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

                                Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

                                Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.

                                  Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%

                                  Adamas Pharmaceuticals, Inc. (ADMS) saw its shares rise above 5% in the last trading session.

                                    Mylan (MYL) Announces Multiple Generic Launches in the U.S.

                                    Mylan (MYL) announced quite a few generic launches in the U.S. in Dec 2016.

                                      Mylan/Biocon's Herceptin Biosimilar Phase III Data Published

                                      Mylan (MYL) and partner Biocon's biosimilar version of Herceptin phase III data published in JAMA.

                                        Mylan (MYL) Launches Authorized Generic EpiPen at $300

                                        Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.

                                          Is Cooper Companies (COO) Poised for Earnings Beat in Q4?

                                          The Cooper Companies Inc. (COO) is set to report fourth-quarter fiscal 2016 results after the market closes on Dec 8.